AbbVie has announced a reduction in its first-quarter and fiscal year 2025 earnings per share (EPS) guidance. This adjustment is attributed to expenses related to acquired in-process research and development (IPR&D) and milestones. These expenses are expected to have a pre-tax impact of $248 million, leading to a $0.13 negative effect on both GAAP diluted earnings per share.